RxDoctor Payments Data

Hannah McCallum

Acute Care · Hattiesburg, MSNPI 1295884617

Payments from drug & device makers

$1,169in general payments, 2019–2025

Across 54 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$205
  • Novartis$196
  • Amgen$119
  • Atricure, Inc.$108
  • Bayer$93
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$84
  • plus $364 from 10 others

What the payments were for

  • Food & beverage$1,169100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,169 in reported general payments places this provider in the 70th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$91,807
Medicare patients
683
Services billed
2,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$104,051
EntrestoSacubitril/Valsartan70$52,630
XareltoRivaroxaban21$16,440
BrilintaTicagrelor14$10,211
FarxigaDapagliflozin Propanediol14$7,827
Metoprolol Succinate96$926
Ranolazine ErRanolazine17$663
Amiodarone Hcl56$584
ClopidogrelClopidogrel Bisulfate67$422
Nitroglycerin18$373
Carvedilol67$306
Metoprolol Tartrate75$287
Metolazone17$277
Isosorbide Mononitrate ErIsosorbide Mononitrate56$273
Furosemide47$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$196$52,63070 claims
AstraZenecaBrilinta, Farxiga$50$18,03928 claims
Johnson & JohnsonXarelto$30$16,44021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 223 acute care providers in Mississippi.

Other acute care in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →